|
Regulatory
Matters
|
|
•
|
Counterfeit
medicines |
|
•
|
Efalizumab |
|
•
|
Ephedrine
and kava kava products |
|
•
|
Ergot-derived
dopamine agonists |
|
•
|
Erythropoiesis-stimulating
agents |
|
•
|
Ezetimibe/simvastatin |
|
•
|
Illegal
medicines |
|
•
|
Malaysia
ADR reporting |
| Safety
of Medicines |
|
•
|
Antiepileptics |
|
•
|
Ceftriaxone |
|
•
|
Lenalidomide |
|
•
|
Mitoxantrone |
|
•
|
Natalizumab |
|
•
|
Nelfinavir |
|
•
|
Pyridoxine |
|
•
|
Simvastatin/amiodarone |
|
•
|
Temsirolimus |
|
•
|
Varenicline |
|
•
|
US
FDA unveils new safety web page |
|
Remembering
the thalidomide disaster |
|
Feature
|
|
•
|
Eighteenth
Meeting of the Global Advisory Committee on Vaccine Safety |
|
•
|
Thirty-first
annual meeting of representatives of national centres participating
in the WHO Programme for International Drug Monitoring |
